| Patient | Georgia O'Keeffe |
|---|---|
| Date of birth | 1887-11-15 |
| Identifiers | MRN HR-ET011-SYN-TD; SSN (made up) 000-11-5873 |
| Document date | 1968-04-09 |
| Author | Wendell Ashby, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week retina visit and second loading injection, left eye. [S]
Ms. O'Keeffe returns four weeks after her first aflibercept injection. Lines on her canvases look less bent with the left eye, and the gray spot is smaller. She had a small red patch on the white of the eye after the injection that faded within a week, and no pain, redness, or loss of vision. Her daily Amsler checks show no change in the right eye. She takes the AREDS2 supplement every day and is still painting daily. [S]
| Element | Detail |
|---|---|
| Interval change | Less distortion and a smaller central spot in the left eye |
| After the first injection | Small red patch on the white of the eye that faded within a week; no pain or vision loss |
| Amsler grid | Daily checks; right eye unchanged |
| Adherence | AREDS2 supplement daily |
| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Milder distortion in the left eye; no pain, light sensitivity, flashes, or floaters |
| Constitutional | Negative | No fatigue or weight change |
| Psychiatric | Negative | Encouraged by the change; sleeping well |
3 systems reviewed. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1968-04-09 | Body height | 165 | cm | S |
| 1968-04-09 | Body weight | 55.5 | kg | S |
| 1968-04-09 | Body mass index (BMI) [Ratio] | 20.4 | kg/m2 | S |
| 1968-04-09 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1968-04-09 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1968-04-09 | Heart rate | 68 | /min | S |
| 1968-04-09 | Respiratory rate | 14 | /min | S |
| 1968-04-09 | Body temperature | 36.6 | Cel | S |
| 1968-04-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1968-04-09 | Visual acuity best corrected Left eye by ETDRS eye chart | 64 | {letters} | >=80 | Low | S |
| 1968-04-09 | Macular grid.center subfield thickness by OCT | 322 | um | 200-300 um | High | S |
| 1968-04-09 | Left eye Intraocular pressure | 15 | mm[Hg] | 10-21 mmHg | Normal | S |
Vital signs recorded on 1968-04-09; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Visual acuity | Best-corrected 64 letters left, up from 55 |
| Intraocular pressure | 15 mmHg left before injection |
| Anterior segment | Quiet; no inflammation after the first injection |
| Dilated fundus, left eye | Lesion smaller, with less subretinal fluid |
| Dilated fundus, right eye | Large drusen unchanged; no fluid or hemorrhage |
| OCT, left eye | Residual subretinal fluid; central subfield thickness 322 µm, down from 418 |
| After injection, left eye | Optic nerve head perfused; counts fingers; no pain |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Neovascular (wet) age-related macular degeneration, left eye, with active choroidal neovascularization | active | confirmed | H35.3221 | S — Synthetic modern diagnosis linked to her documented failing eyesight; the historical type of macular degeneration is not recorded. |
| Nonexudative age-related macular degeneration, right eye, intermediate stage | active | confirmed | H35.3112 | S — Synthetic finding in the fellow eye. |
| New distortion (wavy lines) and a blurred central spot with reduced acuity in the left eye; suspected neovascular macular degeneration, urgent retina referral | resolved | confirmed | H53.15 | S — Synthetic presenting concern at the index visit, superseded by the OCT diagnosis at the retina consultation; her failing eyesight is documented (D). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Best-corrected visual acuity (ETDRS letters) | Every injection visit | Completed today | Left 64 letters, up 9 from baseline. The right eye is followed by Amsler grid and dilated examination during loading |
| Imaging | Optical coherence tomography of the macula | Every injection visit | Completed today | Left eye: central subfield thickness 322 µm with residual fluid |
| Examination | Intraocular pressure before and after injection | Every injection visit | Completed today | Before injection 15 mmHg left; after injection, optic nerve perfused and counting fingers |
| Imaging | Fluorescein angiography or OCT angiography | If the response is poor or the picture atypical | Not indicated | Responding as expected to loading, which supports the diagnosis |
| Examination | Dilated examination of the fellow (right) eye | Every injection visit | Completed today | Large drusen unchanged; no fluid |
| Medication safety | Intravitreal injection safety | Every injection visit | Completed today | Small subconjunctival hemorrhage after the first injection, resolved; no inflammation. Second loading dose today |
| Self-management | Teaching on warning signs of endophthalmitis and retinal detachment | Every injection visit | Completed today | Reviewed again |
| Self-management | Daily home Amsler grid, each eye | Daily | Completed today | Daily checks recorded; no change in the right eye |
| Medication safety | AREDS2 supplement for intermediate AMD | Daily, long term | Completed today | Taking it daily |
| Referral | Low-vision rehabilitation, with home fall-risk review and a driving assessment | Once central vision is reduced; review as vision changes | Referred | Evaluation booked for next month |
| Survey | Depression screen (PHQ-2) | At follow-up, because vision loss raises the risk of depression; periodically at 65 or older | Due | Planned at the July primary care review |
Goal progress:
Guideline basis: Age-Related Macular Degeneration Preferred Practice Pattern (2024); CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026)
Follow-up: Retina visit in four weeks for the third loading injection. Next scheduled visit 1968-05-07: eight-week retina follow-up with OCT and third injection. [S]